Embecta seeks high growth with low tech
The diabetes-focused Becton Dickinson spinoff intends to spend – but can it compete in insulin pumps?
New Glaxo: it’s all about the late-stage assets
Walmsley wins some breathing space but, for ambitious new growth targets to be met, the pipeline must start delivering.
Big pharma spinouts grow up
Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.